{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T04:48:16Z","timestamp":1794718096628,"version":"4.9.1"},"reference-count":71,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>High-density lipoprotein cholesterol (HDL-C) has long been inversely associated with atherosclerotic cardiovascular disease risk, but pharmacologic efforts to raise HDL-C have consistently failed to reduce cardiovascular events. This has shifted focus from HDL quantity to quality, emphasizing functional properties such as cholesterol efflux, antioxidative capacity, and anti-inflammatory activity. Dysfunctional HDL, often modified by oxidative and inflammatory processes mediated by myeloperoxidase, loses its ability to promote reverse cholesterol transport, support endothelial function, and suppress vascular inflammation. Advanced proteomic and lipidomic studies have revealed compositional remodeling that underlies HDL\u2019s functional heterogeneity and disease-specific signatures. Functional measures like cholesterol efflux capacity and cell-free HDL assays correlate more strongly with cardiovascular outcomes than static HDL-C levels, providing a more accurate index of vascular protection. Despite the promising therapies such as cholesterol ester transfer protein (CETP) inhibitors, niacin, and apolipoprotein A-I infusions (reconstituted high-density lipoprotein (CSL112)), none have yet demonstrated definitive event reduction. Future directions include standardizing HDL functional assays, prioritizing quality over concentration, and integrating HDL-targeted and metabolic therapies, including glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose transport 2 (SGLT2) inhibitors, to restore HDL\u2019s protective phenotype and redefine preventive cardiology.<\/jats:p>","DOI":"10.1097\/crd.0000000000001126","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:00:18Z","timestamp":1763096418000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["High-Density Lipoprotein Dysfunction and Atherosclerotic Cardiovascular Disease: From Quantity to Quality"],"prefix":"10.1097","author":[{"given":"Amogh Jyothi","family":"Arun","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Kaneki","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Baig","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Departments of Cardiology and Medicine, Westchester Medical Center, New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"R1-20251114","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1161\/CIRCRESAHA.123.321563","article-title":"HDL function and atherosclerosis: reactive dicarbonyls as promising targets of therapy.","volume":"132","author":"Linton","year":"2023","journal-title":"Circ Res"},{"key":"R2-20251114","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease.","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"R3-20251114","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.2174\/0929867325666180530110543","article-title":"Biological consequences of dysfunctional HDL.","volume":"26","author":"Pirillo","year":"2019","journal-title":"Curr Med Chem"},{"key":"R4-20251114","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","article-title":"High-density lipoprotein revisited: biological functions and clinical relevance.","volume":"44","author":"von Eckardstein","year":"2023","journal-title":"Eur Heart J"},{"key":"R5-20251114","doi-asserted-by":"crossref","first-page":"6066","DOI":"10.2174\/0929867328666210208182326","article-title":"The yin and yang of high-density lipoprotein and atherosclerotic cardiovascular disease: focusing on functionality and cholesterol efflux to reframe the HDL hypothesis.","volume":"28","author":"Ganjali","year":"2021","journal-title":"Curr Med Chem"},{"key":"R6-20251114","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11883-025-01308-9","article-title":"High density lipoprotein particle composition, functionality, deficiency, and atherosclerotic cardiovascular disease risk: a review.","volume":"27","author":"Schaefer","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"R7-20251114","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41569-021-00538-z","article-title":"High-density lipoproteins, reverse cholesterol transport and atherogenesis.","volume":"18","author":"Pownall","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"R8-20251114","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1161\/ATVBAHA.117.307025","article-title":"From high-density lipoprotein cholesterol to measurements of function: prospects for the development of tests for high-density lipoprotein functionality in cardiovascular disease.","volume":"38","author":"Sacks","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R9-20251114","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ni.2784","article-title":"High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3.","volume":"15","author":"De Nardo","year":"2014","journal-title":"Nat Immunol"},{"key":"R10-20251114","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1161\/CIRCULATIONAHA.110.961193","article-title":"High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide.","volume":"122","author":"Suzuki","year":"2010","journal-title":"Circulation"},{"key":"R11-20251114","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bph.13319","article-title":"High-density lipoprotein inhibits human M1 macrophage polarization through redistribution of caveolin-1.","volume":"173","author":"Lee","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R12-20251114","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/jir.2019.0029","article-title":"High-density lipoproteins decrease proinflammatory activity and modulate the innate immune response.","volume":"39","author":"Taborda","year":"2019","journal-title":"J Interferon Cytokine Res"},{"key":"R13-20251114","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/imm.13348","article-title":"The role of high-density lipoprotein in the regulation of the immune response: implications for atherosclerosis and autoimmunity.","volume":"164","author":"Fernandes das Neves","year":"2021","journal-title":"Immunology"},{"key":"R14-20251114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosis.2011.06.045","article-title":"Emerging role of high density lipoproteins as a player in the immune system.","volume":"220","author":"Norata","year":"2012","journal-title":"Atherosclerosis"},{"key":"R15-20251114","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.2174\/0929867325666180316115726","article-title":"Dysfunctional HDL as a therapeutic target for atherosclerosis prevention.","volume":"26","author":"Ossoli","year":"2019","journal-title":"Curr Med Chem"},{"key":"R16-20251114","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1161\/ATVBAHA.112.300133","article-title":"High-density lipoprotein function, dysfunction, and reverse cholesterol transport.","volume":"32","author":"Fisher","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R17-20251114","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3390\/antiox11030556","article-title":"Understanding myeloperoxidase-induced damage to HDL structure and function in the vessel wall: implications for HDL-based therapies.","volume":"11","author":"Marsche","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"R18-20251114","doi-asserted-by":"crossref","first-page":"30825","DOI":"10.1074\/jbc.M109.047605","article-title":"Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle.","volume":"284","author":"Undurti","year":"2009","journal-title":"J Biol Chem"},{"key":"R19-20251114","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1042\/BJ20121210","article-title":"Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCl).","volume":"449","author":"Hadfield","year":"2013","journal-title":"Biochem J"},{"key":"R20-20251114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.freeradbiomed.2017.11.012","article-title":"Characterization of covalent modifications of HDL apoproteins by endogenous oxidized phospholipids.","volume":"115","author":"Gao","year":"2018","journal-title":"Free Radic Biol Med"},{"key":"R21-20251114","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.freeradbiomed.2013.02.004","article-title":"High-density lipoprotein nitration and chlorination catalyzed by myeloperoxidase impair its effect of promoting endothelial repair.","volume":"60","author":"Pan","year":"2013","journal-title":"Free Radic Biol Med"},{"key":"R22-20251114","doi-asserted-by":"crossref","first-page":"118565","DOI":"10.1016\/j.atherosclerosis.2024.118565","article-title":"Relationships between HDL subpopulation proteome and HDL function in overweight\/obese people with and without coronary heart disease.","volume":"397","author":"Vaisar","year":"2024","journal-title":"Atherosclerosis"},{"key":"R23-20251114","doi-asserted-by":"crossref","first-page":"15526","DOI":"10.3390\/ijms242115526","article-title":"Proteomic determinants of variation in cholesterol efflux: observations from the dallas heart study.","volume":"24","author":"Gangwar","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R24-20251114","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1161\/ATVBAHA.118.311607","article-title":"Distinct proteomic signatures in 16 HDL (high-density lipoprotein) subspecies.","volume":"38","author":"Furtado","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R25-20251114","doi-asserted-by":"crossref","first-page":"184201","DOI":"10.1016\/j.bbamem.2023.184201","article-title":"Unravelling the influence of surface lipids on the structure, dynamics and interactome of high-density lipoproteins.","volume":"1865","author":"Malajczuk","year":"2023","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"R26-20251114","doi-asserted-by":"crossref","first-page":"6786","DOI":"10.3390\/ijms23126786","article-title":"Lipidomic approaches to study HDL metabolism in patients with central obesity diagnosed with metabolic syndrome.","volume":"23","author":"Mocciaro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R27-20251114","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1021\/acs.jproteome.1c00429","article-title":"Reproducible determination of high-density lipoprotein proteotypes.","volume":"20","author":"Goetze","year":"2021","journal-title":"J Proteome Res"},{"key":"R28-20251114","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3390\/biom12101439","article-title":"Integrated quantitative targeted lipidomics and proteomics reveal unique fingerprints of multiple metabolic conditions.","volume":"12","author":"Ivanova","year":"2022","journal-title":"Biomolecules"},{"key":"R29-20251114","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events.","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"R30-20251114","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MOL.0000000000000589","article-title":"From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants.","volume":"30","author":"Rhainds","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"R31-20251114","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/cells10030574","article-title":"High density lipoprotein cholesterol efflux capacity and atherosclerosis in cardiovascular disease: pathophysiological aspects and pharmacological perspectives.","volume":"10","author":"Adorni","year":"2021","journal-title":"Cells"},{"key":"R32-20251114","doi-asserted-by":"crossref","first-page":"120574","DOI":"10.1016\/j.cca.2025.120574","article-title":"High-density lipoprotein in cardiovascular diseases: from high quantity to high quality.","volume":"578","author":"Zhang","year":"2026","journal-title":"Clin Chim Acta"},{"key":"R33-20251114","doi-asserted-by":"crossref","first-page":"e165370","DOI":"10.1172\/JCI165370","article-title":"Cell-free, high-density lipoprotein-specific phospholipid efflux assay predicts incident cardiovascular disease.","volume":"133","author":"Sato","year":"2023","journal-title":"J Clin Invest"},{"key":"R34-20251114","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2020.04.015","article-title":"High density lipoprotein functionality and cardiovascular events and mortality: a systematic review and meta-analysis.","volume":"302","author":"Soria-Florido","year":"2020","journal-title":"Atherosclerosis"},{"key":"R35-20251114","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.amjcard.2015.11.033","article-title":"Prognostic usefulness of serum cholesterol efflux capacity in patients with coronary artery disease.","volume":"117","author":"Zhang","year":"2016","journal-title":"Am J Cardiol"},{"key":"R36-20251114","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (atherothrombosis intervention in metabolic syndrome with low HDL\/high triglyceride and impact on Global Health Outcomes).","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R37-20251114","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacl.2018.07.007","article-title":"Cardiovascular outcomes during extended follow-up of the AIM-HIGH trial cohort.","volume":"12","author":"Probstfield","year":"2018","journal-title":"J Clin Lipidol"},{"key":"R38-20251114","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11883-014-0398-0","article-title":"HDL hypothesis: where do we stand now?","volume":"16","author":"Tariq","year":"2014","journal-title":"Curr Atheroscler Rep"},{"key":"R39-20251114","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jacl.2015.01.008","article-title":"Is HPS2-THRIVE the death knell for niacin?","volume":"9","author":"Toth","year":"2015","journal-title":"J Clin Lipidol"},{"key":"R40-20251114","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ahj.2010.11.017","article-title":"The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL\/high triglycerides: impact on Global Health outcomes (AIM-HIGH).","volume":"161","year":"2011","journal-title":"Am Heart J"},{"key":"R41-20251114","doi-asserted-by":"crossref","first-page":"159063","DOI":"10.1016\/j.bbalip.2021.159063","article-title":"HDL cholesterol concentrations and risk of atherosclerotic cardiovascular disease\u2014insights from randomized clinical trials and human genetics.","volume":"1867","author":"Kjeldsen","year":"2022","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"R42-20251114","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jacc.2018.10.072","article-title":"Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week.","volume":"73","author":"Armitage","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R43-20251114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.phrs.2017.12.028","article-title":"Present therapeutic role of cholesteryl ester transfer protein inhibitors.","volume":"128","author":"Ferri","year":"2018","journal-title":"Pharmacol Res"},{"key":"R44-20251114","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors.","volume":"122","author":"Tall","year":"2018","journal-title":"Circ Res"},{"key":"R45-20251114","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1161\/ATVBAHA.122.318243","article-title":"CSL112 infusion rapidly increases APOA1 exchange rate via specific serum amyloid-poor HDL subpopulations when administered to patients post-myocardial infarction.","volume":"43","author":"Didichenko","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R46-20251114","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/ATVBAHA.114.303720","article-title":"CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.","volume":"34","author":"Gille","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R47-20251114","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/ATVBAHA.118.310538","article-title":"CSL112 (apolipoprotein A-I [Human]) enhances cholesterol efflux similarly in healthy individuals and stable atherosclerotic disease patients.","volume":"38","author":"Gille","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R48-20251114","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s11883-022-01025-7","article-title":"ApoA-I infusion therapies following acute coronary syndrome: past, present, and future.","volume":"24","author":"Kalayci","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"R49-20251114","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/j.jacl.2024.01.009","article-title":"High-density lipoprotein infusion therapy: a review.","volume":"18","author":"Brewer","year":"2024","journal-title":"J Clin Lipidol"},{"key":"R50-20251114","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.3390\/jcm10245897","article-title":"Modification of high-density lipoprotein functions by diet and other lifestyle changes: a systematic review of randomized controlled trials.","volume":"10","author":"Sanllorente","year":"2021","journal-title":"J Clin Med"},{"key":"R51-20251114","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/MOL.0000000000000317","article-title":"Modulating cholesterol efflux capacity to improve cardiovascular disease.","volume":"27","author":"Brownell","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"R52-20251114","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/978-3-319-09665-0_18","article-title":"HDL and lifestyle interventions.","volume":"224","author":"Escola-Gil","year":"2015","journal-title":"Handb Exp Pharmacol"},{"key":"R53-20251114","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1016\/j.clinthera.2015.07.021","article-title":"Targeting high-density lipoproteins to reduce cardiovascular risk: what is the evidence?","volume":"37","author":"Barter","year":"2015","journal-title":"Clin Ther"},{"key":"R54-20251114","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCRESAHA.114.300760","article-title":"High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies.","volume":"114","author":"Feig","year":"2014","journal-title":"Circ Res"},{"key":"R55-20251114","doi-asserted-by":"crossref","first-page":"167761","DOI":"10.1016\/j.bbadis.2025.167761","article-title":"Sepsis and high-density lipoproteins: pathophysiology and potential new therapeutic targets.","volume":"1871","author":"Parolini","year":"2025","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"R56-20251114","doi-asserted-by":"crossref","first-page":"12965","DOI":"10.3390\/ijms232112965","article-title":"Impact of high-density lipoproteins on sepsis.","volume":"23","author":"De Geest","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R57-20251114","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13054-020-02860-3","article-title":"High-density lipoproteins during sepsis: from bench to bedside.","volume":"24","author":"Tanaka","year":"2020","journal-title":"Crit Care"},{"key":"R58-20251114","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/ALN.0000000000003155","article-title":"Reconstituted high-density lipoprotein therapy improves survival in mouse models of sepsis.","volume":"132","author":"Tanaka","year":"2020","journal-title":"Anesthesiology"},{"key":"R59-20251114","doi-asserted-by":"crossref","first-page":"159606","DOI":"10.1016\/j.bbalip.2025.159606","article-title":"Production, characterization and biodistribution of therapeutic high-density lipoprotein-like nanoparticles reconstituted with or without histidine-tagged recombinant ApoA1.","volume":"1870","author":"Rosanaly","year":"2025","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"R60-20251114","doi-asserted-by":"crossref","first-page":"e71235","DOI":"10.1371\/journal.pone.0071235","article-title":"Reconstituted high-density lipoprotein modulates activation of human leukocytes.","volume":"8","author":"Spirig","year":"2013","journal-title":"PLoS One"},{"key":"R61-20251114","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ijbiomac.2021.12.009","article-title":"High-density lipoproteins and immune response: a review.","volume":"195","author":"Grao-Cruces","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"R62-20251114","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.5551\/jat.RV22020","article-title":"Bridging the gap between the bench and bedside: clinical applications of high-density lipoprotein function.","volume":"31","author":"Endo","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"R63-20251114","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes.","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"R64-20251114","doi-asserted-by":"crossref","first-page":"10202","DOI":"10.1038\/srep10202","article-title":"Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 diabetes mellitus: a meta-analysis.","volume":"5","author":"Song","year":"2015","journal-title":"Sci Rep"},{"key":"R65-20251114","doi-asserted-by":"crossref","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-like peptide-1: new regulator in lipid metabolism.","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab J"},{"key":"R66-20251114","doi-asserted-by":"crossref","first-page":"10164","DOI":"10.3390\/ijms241210164","article-title":"Novel antidiabetic agents and their effects on lipid profile: a single shot for several cardiovascular targets.","volume":"24","author":"Piccirillo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R67-20251114","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/03007995.2024.2442027","article-title":"Glucagon-like peptide 1 receptor agonists modestly reduced low-density lipoprotein cholesterol and total cholesterol levels independent of weight reduction: a meta-analysis and meta-regression of placebo controlled randomized controlled trials.","volume":"41","author":"Rivera","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"R68-20251114","doi-asserted-by":"crossref","first-page":"109044","DOI":"10.1016\/j.jdiacomp.2025.109044","article-title":"The effects of SGLT2 inhibitors and GLP-1 receptor agonists on the triglyceride to HDL cholesterol ratio and the triglyceride-glucose index in patients with type 2 diabetes.","volume":"39","author":"Voziki","year":"2025","journal-title":"J Diabetes Complications"},{"key":"R69-20251114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12920-024-01826-6","article-title":"Proteome-wide mendelian randomization investigates potential associations in heart failure and its etiology: emphasis on PCSK9.","volume":"17","author":"Lin","year":"2024","journal-title":"BMC Med Genomics"},{"key":"R70-20251114","doi-asserted-by":"crossref","first-page":"100621","DOI":"10.1016\/j.lansea.2025.100621","article-title":"Identification of protein targets for dyslipidaemia and cardiovascular diseases among people with South Asian ancestry: a mendelian randomisation study.","volume":"39","author":"Wu","year":"2025","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"R71-20251114","doi-asserted-by":"crossref","first-page":"2500003","DOI":"10.1002\/ggn2.202500003","article-title":"Proteome-wide mendelian randomization identifies candidate causal proteins for cardiovascular diseases.","volume":"6","author":"Li","year":"2025","journal-title":"Adv Genet (Hoboken)"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T05:00:26Z","timestamp":1763096426000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":71,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001126","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]}}}